As with many conditions, the kind of care a patient receives can depend on where they live. This can be especially true for dermatology patients needing things like phototherapy. Other factors, like cost and fear, can also impede the treatment process.
As patients go through the process of treating their plaque psoriasis, there can be different levels of success depending on a number of situations. As a result, measuring success can be a challenge as well.
Erelzi, a biosimilar of Enbrel (etanercept), has received FDA approval. Biosimilars are defined by the organization as being “highly similar to an FDA-approved biological product” while demonstrating “clinically meaningful differences in terms of safety and effectiveness.”